Test Code PCDES Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum
Ordering Guidance
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, see Autoimmune Neurology Test Ordering Guide.
When more than one evaluation is ordered on the same order number, the duplicate test will be canceled.
For a list of antibodies performed with each evaluation, see Autoimmune Neurology Antibody Matrix.
This test should not be requested for patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed or canceled if radioactivity remains.
Necessary Information
Provide the following information:
-Relevant clinical information
-Ordering provider name, phone number, mailing address, and e-mail address
Specimen Required
Patient Preparation: For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 4 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Evaluating children with autoimmune central nervous system disorders using serum specimens
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
PCSI | Peds Autoimmune CNS Interp, S | No | Yes |
AMPCS | AMPA-R Ab CBA, S | No | Yes |
ANN1S | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
CS2CS | CASPR2-IgG CBA, S | No | Yes |
DPPCS | DPPX Ab CBA, S | No | Yes |
GABCS | GABA-B-R Ab CBA, S | No | Yes |
GD65S | GAD65 Ab Assay, S | Yes | Yes |
GFAIS | GFAP IFA, S | No | Yes |
LG1CS | LGI1-IgG CBA, S | No | Yes |
GL1IS | mGluR1 Ab IFA, S | No | Yes |
MOGFS | MOG FACS, S | Yes | Yes |
NCDIS | Neurochondrin IFA, S | No | Yes |
NMDCS | NMDA-R Ab CBA, S | No | Yes |
NMOFS | NMO/AQP4 FACS, S | Yes | Yes |
PCATR | Purkinje Cell Cytoplasmic Ab Type Tr | No | Yes |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
AN1BS | ANNA-1 Immunoblot, S | No | No |
AN2BS | ANNA-2 Immunoblot, S | No | No |
DPPTS | DPPX Ab IFA Titer, S | No | No |
GFACS | GFAP CBA, S | No | No |
GFATS | GFAP IFA Titer, S | No | No |
GL1CS | mGluR1 Ab CBA, S | No | No |
GL1TS | mGluR1 Ab IFA Titer, S | No | No |
MOGTS | MOG FACS Titer, S | No | No |
NMDIS | NMDA-R Ab IF Titer Assay, S | No | No |
NMOTS | NMO/AQP4 FACS Titer, S | No | No |
PCTBS | PCA-Tr Immunoblot, S | No | No |
AN1TS | ANNA-1 Titer, S | No | No |
GABIS | GABA-B-R Ab IF Titer Assay, S | No | No |
NCDCS | Neurochondrin CBA, S | No | No |
NCDTS | Neurochondrin IFA Titer, S | No | No |
PCTTS | PCA-Tr Titer, S | No | No |
AMPIS | AMPA-R Ab IF Titer Assay, S | No | No |
Method Name
AMPCS, CS2CS, DPPCS, GABCS, GFACS, LG1CS, GL1CS, NCDCS, NMDCS: Cell Binding Assay (CBA)
MOGFS, MOGTS, NMOFS, NMOTS: Flow Cytometry
AMPIS, ANN1S, AN1TS, DPPTS, GABIS, GFAIS, GFATS, GL1IS, GL1TS, NCDIS, NCDTS, NMDIS, PCATR, PCTTS: Indirect Immunofluorescence (IFA)
GD65S: Radioimmunoassay (RIA)
AN1BS, AN2BS, PCTBS: Immunoblot (IB)
PCSI: Medical Interpretation
Reporting Name
Peds Autoimm Enceph CNS, SSpecimen Type
SerumSpecimen Minimum Volume
2 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Clinical Information
Autoimmune encephalitis and myelitis is increasingly recognized as a cause of central nervous system disease in children and adolescents. N-methyl-D-aspartate receptor antibody (NMDA-R) encephalitis and myelin oligodendrocyte glycoprotein (MOG) autoimmunity are most common, though other entities, including aquaporin-4 autoimmunity, contactin-associated protein-like 2 (CASPR2) autoimmunity, autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy, and paraneoplastic encephalomyelopathies, may also occur in children.
Reference Values
Test ID |
Reporting name |
Methodology* |
Reference value |
PCSI |
Peds Autoimmune CNS Interp, S |
Medical interpretation |
Interpretive report |
AMPCS |
AMPA-R Ab CBA, S |
CBA |
Negative |
ANN1S |
Anti-Neuronal Nuclear Ab, Type 1 |
IFA |
Negative |
CS2CS |
CASPR2-IgG CBA, S |
CBA |
Negative |
DPPCS |
DPPX Ab CBA, S |
CBA |
Negative |
GABCS |
GABA-B-R Ab CBA, S |
CBA |
Negative |
GD65S |
GAD65 Ab Assay, S |
RIA |
≤0.02 nmol/L Reference values apply to all ages. |
GFAIS |
GFAP IFA, S |
IFA |
Negative |
LG1CS |
LGI1-IgG CBA, S |
CBA |
Negative |
GL1IS |
mGluR1 Ab IFA, S |
IFA |
Negative |
NCDIS |
Neurochondrin IFA, S |
IFA |
Negative |
MOGFS |
MOG FACS, S |
FACS |
Negative |
NMDCS |
NMDA-R Ab CBA, S |
CBA |
Negative |
NMOFS |
NMO/AQP4 FACS, S |
FACS |
Negative |
PCATR |
 Purkinje Cell Cytoplasmic Ab Type Tr |
IFA |
Negative |
Reflex Information:
Test ID |
Reporting name |
Methodology |
Reference value |
AMPIS |
AMPA-R Ab IF Titer Assay, S |
IFA |
<1:240 |
AN1BS |
ANNA-1 Immunoblot, S |
IB |
Negative |
AN1TS |
ANNA-1 Titer, S |
IFA |
<1:240 |
AN2BS |
ANNA-2 Immunoblot, S |
IB |
Negative |
DPPTS |
DPPX Ab IFA Titer, S |
IFA |
<1:240 |
GABIS |
GABA-B-R Ab IF Titer Assay, S |
IFA |
<1:240 |
GFACS |
GFAP CBA, S |
CBA |
Negative |
GFATS |
GFAP IFA Titer, S |
IFA |
<1:240 |
GL1CS |
mGluR1 Ab CBA, S |
CBA |
Negative |
GL1TS |
mGluR1 Ab IFA Titer, S |
IFA |
<1:240 |
MOGTS |
MOG FACS Titer, S |
FACS |
<1:20 |
NCDCS |
Neurochondrin CBA, S |
CBA |
Negative |
NCDTS |
Neurochondrin IFA Titer, S |
IFA |
<1:240 |
NMDIS |
NMDA-R Ab IF Titer Assay, S |
IFA |
<1:240 |
NMOTS |
NMO/AQP4 FACS Titer, S |
FACS |
<1:5 |
PCTTS |
PCA-Tr Titer, S |
IFA |
<1:240 |
PCTBS |
PCA-Tr Immunoblot, S |
IB |
Negative |
*Methodology abbreviations:
Immunofluorescence assay (IFA)
Cell-binding assay (CBA)
Fluorescence activated cell sorting assay (FACS)
Radioimmunoassay (RIA)
Immunoblot (IB)
**Neuron-restricted patterns of IgG staining that do not fulfill criteria for ANNA-1, ANNA-2, or PCA-Tr may be reported as "unclassified anti-neuronal IgG." Complex patterns that include non-neuronal elements may be reported as "uninterpretable."
Day(s) Performed
Profile tests: Monday through Sunday; Reflex tests: Varies
Report Available
8 to 12 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86341
86363
86053
86255 x 11
86256 AMPIS (if appropriate)
84182 AN1BS (if appropriate)
86256 AN1TS (if appropriate)
84182 AN2BS (if appropriate)
86256 DPPTS (if appropriate)
86256 GABIS (if appropriate)
86255 GFACS (if appropriate)
86256 GFATS (if appropriate)
86255 GL1CS (if appropriate)
86256 GL1TS (if appropriate)
86363 MOGTS (if appropriate)
86255 NCDCS (if appropriate)
86256 NCDTS (if appropriate)
86256 NMDIS (if appropriate)
86053 NMOTS (if appropriate)
84182 PCTBS (if appropriate)
86256 PCTTS (if appropriate)
Special Instructions
Forms
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.